首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
【24h】

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

机译:Pembrolizumab单疗法在老年PD-L1阳性晚期非小细胞肺癌中的安全性和有效性:来自Keynote-010,Keynote-024和Keynote-042研究的汇总分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: Most lung cancer diagnoses occur in elderly patients, who are underrepresented in clinical trials. We present a pooled analysis of safety and efficacy in elderly patients (>= 75 years) who received pembrolizumab (a programmed death 1 inhibitor) for advanced non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1)-positive tumors.
机译:目的:大多数肺癌诊断发生在老年患者中,在临床试验中受到尊重。 我们在老年患者(> = 75岁)中,为先进的非小细胞肺癌(NSCLC)的老年患者(> = 75岁)的安全性和疗效进行了汇总分析(> = 75岁),具有编程死亡配体1(PD-L1) - 肌瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号